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OBJECTIVES We evaluated the relationship between the degree of heparin anticoagulation and clinical
efficacy and bleeding in patients undergoing contemporary percutaneous coronary interven-
tion (PCI) with stent implantation.
BACKGROUND Despite universal acceptance of heparin anticoagulation as a standard of care in PCI,
considerable controversy still exists regarding the appropriate dosing of heparin.
METHODS The study population (n  2,064) comprised all patients enrolled in the Enhanced
Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. The
index activated clotting time (ACT) was defined as the ACT measured after the last heparin
dose and before first device activation and was correlated with outcome and bleeding events.
RESULTS No association was observed between decreasing ACT levels and the rate of ischemic events
in the treatment or placebo arms. The incidence of the primary composite end point (death,
myocardial infarction, urgent target vessel revascularization, and thrombotic bailout glyco-
protein IIb/IIIa inhibitor therapy at 48 h) was actually lowest in the lowest ACT tertile for
both the placebo (10.0%) and treatment groups (6.1%). When analyzed by tertile, major
bleeding rates did not increase in the lowest ACT tertile in patients given placebo (0.6%)
versus those receiving eptifibatide (0.7%). Major bleeding rates increased as the ACT
increased in the eptifibatide-treated patients.
CONCLUSIONS Ischemic end points in patients undergoing contemporary PCI with stent placement do not
increase by decreasing ACT levels, at least to a level of 200 s. Bleeding events do increase with
increasing ACT levels and are enhanced with eptifibatide treatment. An ACT of 200 to 250 s
is reasonable in terms of efficacy and safety with the use of contemporary technology and
pharmacotherapy. (J Am Coll Cardiol 2003;41:386–93) © 2003 by the American College
of Cardiology Foundation
Since the first coronary angioplasty procedure performed
more than two decades ago, intravenous unfractionated
heparin has been the cornerstone of antithrombotic therapy
during percutaneous coronary intervention (PCI). Despite
universal acceptance of heparin anticoagulation as a stan-
dard of care in coronary interventions, there is still contro-
versy about the appropriate dosing of heparin. Reports
evaluating heparin anticoagulation during PCI have primar-
ily consisted of registry reports or small case-control studies
(1–4), with analyses of a larger experience focusing on
balloon angioplasty trials (5). The purpose of this study was
to evaluate the relationship between the degree of antico-
agulation achieved with heparin and clinical efficacy and
bleeding in patients undergoing PCI with stent placement.
METHODS
Study population. To represent the current practice of
PCI with stent placement, we chose patients enrolled in the
Enhanced Suppression of the Platelet IIb/IIIa Receptor
with Integrilin Therapy (ESPRIT) trial for our study
population. The details of the ESPRIT trial have been
previously published (6). Briefly, ESPRIT was a random-
ized, double-blinded, placebo-controlled, parallel-group,
clinical trial conducted at 92 centers in the U.S. and
Canada. Patients included in the study had coronary artery
disease and were scheduled to undergo PCI with stent
implantation in a native coronary artery. In the opinion of
the treating physician, these patients would not be routinely
treated with a platelet glycoprotein (GP) IIb/IIIa inhibitor
during PCI. The enrollment period was from June 3, 1999
through February 4, 2000. Patients were randomly assigned
to receive placebo or eptifibatide treatment. Among the
2,064 patients enrolled in ESPRIT, the baseline demo-
graphic and angiographic characteristics were balanced be-
tween the placebo and treatment groups. The index acti-
vated clotting time (ACT), according to patient
characteristics, is shown in Table 1. Approximately 20% of
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patients were classified as having an acute coronary syn-
drome within 48 h or acute ST-segment elevation myocar-
dial infarction (MI) within seven days before the interven-
tion. More than 98% of patients randomized underwent
PCI; at least one stent was placed in 97.2% of these PCI
patients. More than 20 stent types were used during the
course of the study. Over 97% of patients received a
thienopyridine, with clopidogrel being administered in 98%
of cases.
Study protocol. The ESPRIT protocol stipulated that
patients receive pretreatment with aspirin and a thienopy-
ridine (either ticlopidine or clopidogrel, with use of a
loading dose) on the day of randomization, before the
initiation of PCI. A weight-adjusted heparin regimen was
recommended (initial bolus of 60 U/kg, not to exceed 6,000
U) to target an ACT of 200 to 300 s. For patients who had
received an intravenous heparin infusion within the previous
6 h, ACT was determined on arrival to the laboratory. If the
ACT was 200 s, additional heparin was administered
according to the following guidelines: ACT150: 40-U/kg
bolus; 150–174: 25-U/kg bolus; and 175–199: 10-U/kg
bolus. The ACT measured after the last heparin dose and
before the first device activation was defined as the “index”
(maximum pre-procedural) ACT.
The study drug was started immediately before the
initiation of the PCI procedure; all PCI procedures were
performed according to local standards. High-pressure bal-
loon inflation for stent deployment was encouraged, and any
stent type with regulatory agency approval could be im-
planted. Patients were allocated to receive placebo or epti-
fibatide in a 1:1 distribution. The eptifibatide dosing con-
sisted of a bolus dose of 180 g/kg, immediately followed by
a continuous infusion of 2.0 g/kg per min (or 1.0 g/kg
per min in patients with serum creatinine 2 mg/dl). A
second bolus dose of eptifibatide of 180 g/kg was admin-
istered 10 min after the first. The infusion continued until
hospital discharge or up to 18 to 24 h. Activation of the PCI
device (balloon, stent, or other interventional device) was
permitted at any time after the first bolus.
Baseline blood counts (hemoglobin, hematocrit, and
platelet count) and cardiac enzymes were obtained before
device activation. Blood counts were measured at 24 h and
when there was any clinical suspicion of bleeding; cardiac
enzymes were measured at 6, 12, 18, and 24 h and analyzed
in the core laboratory. The index ACT was used to reflect
the anticoagulation state at the time of device activation.
Vascular access sheaths were to be immediately removed
with either a femoral arteriotomy closure device or external
Abbreviations and Acronyms
ACT  activated clotting time
CK-MB  creatine kinase, MB isoenzyme
ESPRIT  Enhanced Suppression of the Platelet
IIb/IIIa Receptor with Integrilin
Therapy trial
GP  glycoprotein
IMPACT-II  Integrilin to Minimize Platelet
Aggregation and Coronary Thrombosis-
II trial
MI  myocardial infarction
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarction
trial
TVR  target vessel revascularization




Females 270 (235, 309) 0.138
Males 266 (231, 306)
Country
U.S. 265 (231, 304) 0.021
Canada 273 (234, 320)
History of MI
Yes 270 (234, 307) 0.252
No 265 (231, 306)
Previous PCI
Yes 273 (239, 307) 0.026
No 265 (230, 306)
Previous CABG
Yes 269 (234, 308) 0.821
No 267 (231, 306)
Diabetes
Yes 267 (232, 309) 0.977
No 267 (232, 306)
Hypertension
Yes 266 (232, 306) 0.568
No 269 (232, 307)
Hypercholesterolemia
Yes 267 (234, 307) 0.201
No 266 (230, 306)
Current smoker
Yes 263 (227, 302) 0.080
No 269 (234, 309)
Stable angina
Yes 271 (235, 312) 0.043
No 265 (230, 304)
Unstable angina/NQMI
2 to 180 days
Yes 267 (232, 311) 0.946
No 267 (231, 306)
Within 2 days
Yes 257 (224, 291) 0.001
No 269 (233, 310)
ST-segment elevation MI within 2 days
Yes 246 (212, 286)  0.001
No 268 (233, 308)
Positive functional test only
Yes 279 (244, 313) 0.004
No 265 (231, 306)
Other anginal equivalent
Yes 278 (230, 309) 0.899
No 267 (232, 306)
*Wilcoxon test of differences in ACT for categorical variables. Two continuous
measures were also examined. Age was not statistically significantly correlated with
ACT (rs  0.03, p  0.125). Weight was significantly correlated (rs  0.08, p 
0.001). Data are presented as the median value (25th and 75th percentiles).
ACT  activated clotting time; CABG  coronary artery bypass graft surgery;
MI  myocardial infarction; NQMI  non–Q-wave myocardial infarction; PCI 
percutaneous coronary intervention.
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compression for hemostasis within 3 to 4 h after completion
of the PCI procedure.
End points. For this study, ACT values were correlated
with the following: the incidence of the primary ischemic
end point for ESPRIT (death, MI, urgent target vessel
revascularization [TVR], and thrombotic bailout GP IIb/
IIIa inhibitor therapy at 48 h); the secondary composite end
point of death, MI, and urgent TVR at 30 days; and the
occurrence of death or MI at 48 h. In the ESPRIT trial,
enzymatic MI was defined as the recording of at least two
creatine kinase, MB isoenzyme (CK-MB) concentrations
greater than or equal to three times the upper limit of
normal within 24 h after PCI. Clinical MI was an event
reported by a site investigator and adjudicated by the
Clinical Events Committee. Bleeding events were quanti-
tatively classified as major or minor according to the
Thrombolysis in Myocardial Infarction (TIMI) trial criteria
(7). To account for the influence of red-cell transfusions on
measured hemoglobin values, the estimated decreases in
hemoglobin were adjusted according to the technique of
Landefeld et al. (8).
Statistical methods. The continuous ACT variable is pre-
sented as the median value and 25th and 75th percentiles.
Wilcoxon tests of differences in ACT were performed for
categorical variables. The associations between ACT and
outcomes were illustrated by dividing ACT into tertiles and
presenting the event rates within each level of ACT. The
relationship between ACT and outcome was determined by
using restricted cubic spline transformations, which allowed
the relationship to be flexible across levels of ACT (9). If the
association was linear, ACT alone was used in all future
tests. If the association was nonlinear, an appropriate
transformation was found. Because the associations between
ACT and outcomes were linear in the ESPRIT data, a
transformation was not required. The associations of ACT
and outcomes were tested by using logistic regression
modeling techniques and univariate statistics after adjusting
for baseline factors. Multivariate models of the primary
outcome and 30-day death or MI were previously developed
by using baseline clinical and angiographic factors.
Interaction terms were used to test the differential effect
of eptifibatide on the relationship between ACT and
outcomes. If the interaction term was significant, tests
within each treatment arm were used to evaluate the ACT
association. If the tests were nonsignificant, evidence was
insufficient to assume that the relationship between ACT
and outcomes was any different between the two treatment
arms.
Rates of bleeding and ACT levels for ESPRIT patients
were compared with those of patients enrolled in the
Integrilin to Minimize Platelet Aggregation and Coronary
Thrombosis (IMPACT)-II trial (10) by using the Pearson
chi-square test and Wilcoxon rank-sum test. All tests used
p  0.05 for the critical value of statistical significance.
Analyses were performed by using SAS statistical software
(SAS Institute, Cary, North Carolina).
RESULTS
The incidences of the primary composite end point; sec-
ondary end point of death, MI, and urgent TVR at 30 days;
and death or MI at 48 h are shown by the index ACT levels
in Figure 1. The degree of heparin anticoagulation, as
measured by ACT, did not significantly affect the rate of
Figure 1. Clinical efficacy of the composite end point of death, myocardial infarction (MI), urgent target vessel revascularization (TVR), and bailout to
open-label treatment for thrombosis; secondary end point of 30-day death, MI, and urgent TVR; and 48-h death or MI by tertile of index activated clotting
time (ACT).
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ischemic events. This lack of association was also similar for
the treatment and placebo arms (p  0.430), and the results
were similar after adjusting for baseline factors. In the
placebo group, the incidence of death or MI at 48 h was
similar among patients distributed by tertiles of maximum
ACT: 9.5% in the lowest tertile, 10.1% in the middle tertile,
and 8.3% in the highest tertile. This same trend was seen
when the incidence of death or MI at 48 h was analyzed by
continuous ACT values (Fig. 2). The incidence of the
primary end point was lowest for the placebo (10.0%) and
treatment groups (6.1%) in the lowest ACT tertile (Fig. 1).
The relative benefit of eptifibatide treatment was also
similar across the tertiles of ACT. The lowest overall event
rate for the primary end point, as well as the lowest
incidence of death or MI in eptifibatide-treated patients was
in the lowest tertile of ACT.
An increase in bleeding was associated with increasing
ACT with eptifibatide treatment, as measured by the
quantitative TIMI bleeding criteria. When bleeding was
analyzed by individual ACT tertiles, rates of major bleeding
were similar only in the lowest tertile with placebo (0.6%)
versus eptifibatide (0.7%) (Fig. 3). Differences between
groups in rates of major bleeding increased as ACT in-
creased (Fig. 4).
Figure 2. Probability of 48-h death or myocardial infarction by index activated clotting time (ACT) for patients receiving treatment versus placebo in the
ESPRIT trial.
Figure 3. Major, minor, and the combination of major and minor bleeding (by TIMI criteria) by tertile of index activated clotting time (ACT).
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The relationship between ACT and bleeding, as well as
between ACT and ischemic events, was further evaluated by
using logistic regression modeling. Increases in ACT among
ESPRIT patients were not associated with significant
changes in overall bleeding rates (TIMI, major and minor)
(p  0.940). Eptifibatide was associated with an increased
risk of bleeding, relative to placebo, after adjusting for ACT
levels (p  0.029)—a relationship that remained constant
across all levels of ACT (p  0.387). Bleeding events were
increased in women (5.5% vs. 2.7%, p  0.004) and in
patients with peripheral vascular disease (7.4% vs. 3.2%, p
0.01). No increases in bleeding rates were observed with
increasing creatinine (p  0.817) or in patients with a
previous MI (p 0.309). Bleeding rates were also calculated
in terms of the amount of heparin given. The total heparin
dose was not correlated to subsequent risk of bleeding (p 
0.757). Even after adjusting for age, weight, and gender, we
found that the total heparin dose was not predictive of
bleeding events (p  0.228). Decreasing ACT levels, in
turn, were not associated with an increased risk of death or
MI in ESPRIT patients (p  0.965).
Eptifibatide treatment was associated with a significant
decrease in the occurrence of death or MI after adjusting for
the ACT level (p  0.002). The relationship between ACT
and death or MI appeared to remain flat for both placebo
and eptifibatide. Regression analyses were also performed to
test for the association between post-procedural enzyme
elevation (post-procedural CK-MB values minus pre-
procedural CK-MB values) and ACT in patients receiving
eptifibatide, as well as in those receiving placebo. There was
no significant relationship between ACT and post-
procedural enzyme elevation (p  0.767) after adjusting for
treatment.
DISCUSSION
The ESPRIT trial, which included the use of 6F guiding
systems, coronary stents, a dual-antiplatelet regimen, and
low-dose, weight-adjusted heparin, afforded us an opportu-
nity to evaluate the relationship between anticoagulation
levels and bleeding and ischemic events in a contemporary
treatment setting. The incidence of ischemic events did not
increase as ACT decreased, at least to a level of 200 s.
Overall, major bleeding events were rare, with a total of 17.
When analyzed continuously by use of a regression model,
the increase in major or minor bleeding corresponding with
increasing ACT did not reach statistical significance. In
addition, the difference in bleeding rates between the
eptifibatide and placebo arms was not statistically different
in the lowest range of ACT values.
The monitoring of anticoagulation by ACT was initially
described in the surgical literature for the purpose of guiding
heparin dosing during cardiopulmonary bypass (11). This
technique gained widespread use in interventional labora-
tories in the late 1980s. Based on empiric observations and
small case-control studies, the initial recommendation for
target ACT levels was in the range of 300 to 350 s (2,3).
In the early 1990s, a series of clinical trials of platelet GP
IIb/IIIa inhibitors was conducted to evaluate the outcomes
of patients undergoing PCI (10,12–15). In the Evaluation
of IIb/IIIa platelet receptor antagonist 7E3 in Preventing
Ischemic Complications (EPIC) trial (12), treatment with
abciximab reduced ischemic complications among high-risk
patients undergoing PCI, but was associated with a dou-
bling of the risk of major bleeding and the need for blood
transfusion. In the PRecursor tO EPILOG (PROLOG)
study (15), a strong trend toward a diminished risk of
bleeding was shown with reductions in weight-adjusted
Figure 4. Probability of bleeding by index activated clotting time (ACT) for patients receiving treatment versus placebo in ESPRIT.
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heparin dosing and early sheath removal. The PROLOG
study also demonstrated that, despite inhibition of platelet
aggregation with GP IIb/IIIa inhibitors, local hemostasis
could be readily achieved after sheath removal if heparin was
first discontinued and coagulation parameters were normal-
ized.
These findings helped shape the design of interventional
studies, including ESPRIT, throughout the 1990s. The
dose of heparin anticoagulation recommended in PCI trials
was empirically decreased during the ensuing decade (Table
2). In ESPRIT, the placebo and treatment arms included
the lowest weight-based regimen that had been used to date.
The goal of200 s was also the lowest target ACT that had
been recommended in a clinical trial of PCI patients. By
collecting index ACTs at the time of device activation, with
systematic recording of hematologic parameters and cardiac
enzymes in all patients after the procedure, we had an
opportunity to analyze the effect of the predictor (ACT) on
the outcomes (MI and bleeding) in a large number of
patients.
The low overall rate of bleeding observed with the
double-bolus dosing of eptifibatide was of particular interest
in the ESPRIT study. The eptifibatide dose was approxi-
mately three times greater than that administered in
IMPACT-II (10), a randomized study of eptifibatide in
4,010 patients undergoing an elective, urgent, or emergency
coronary intervention between November 1993 and No-
vember 1994. Heparin was administered as a 100-U/kg
bolus with a target ACT of 300 to 350 s in IMPACT-II.
Despite the markedly increased level of inhibition of platelet
aggregation in ESPRIT, however, the rates of bleeding were
approximately four times lower than those observed in
IMPACT-II. This difference was seen across all ranges of
ACT (Table 3, Figs. 5 and 6), and the same difference in
bleeding rates between the two studies was seen in the
placebo arm. The significant decrease in bleeding rates
reflects advances in percutaneous catheter-based technology
and arterial access management over the past decade.
During the ESPRIT study, 6F sheaths and guiding cathe-
ters were standard at most study sites. The ESPRIT
protocol contained detailed instructions regarding arterial
access sheath placement, care, and removal, as well as
post-procedural care. A reduction in heparin dosing, smaller
arterial access sheaths, and improved management of the
access site markedly contributed to reduced rates of bleed-
ing, despite more potent levels of platelet inhibition.
Ischemic complications in our study did not increase at
the lowest levels of ACT, even in the placebo group. As
shown in Figure 1, for the 48-h ischemic end points, the
rates were similar across tertiles of ACT. This is the first
published report of low ischemic complication rates with
decreasing ACT levels in a heparin-only group of patients
undergoing PCI with stenting—a finding that remained
constant at both the 48-h and 30-day end points. Bleeding
Table 2. Comparison of Different Heparin Doses in Clinical Trials in the 1990s
Study Study Drug Dates Heparin Dose Target ACT (s)
EPIC (12) Abciximab 1991–1992 10,000–12,000 U/kg (maximum 20,000) 300–350
IMPACT-II (10) Eptifibatide November 1993 to November 1994 100 U/kg 300–350
RESTORE (14) Tirofiban January to December 1995 150 U/kg (maximum 10,000) 300–400
EPILOG (13) Abciximab February to December 1995 100 U/kg (placebo) 300
70 U/kg (abciximab) 200
EPISTENT* Abciximab 1996–1997 100 U/kg (placebo) 300
70 U/kg (abciximab) 200
ESPRIT (6) Eptifibatide 1999–2000 60 U/kg 200–300
*Source: The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty–controlled trial to assess safety of coronary stenting with use of platelet
glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.
ACT  activated clotting time; EPIC  Evaluation of IIb/IIIa platelet receptor antagonist in Preventing Ischemic Complications; EPILOG  Evaluation in PTCA to
Improve Long-term Outcome with abciximab GP IIb/IIIa blockade; EPISTENT  Evaluation of IIb/IIIa Platelet Inhibition for Stenting; ESPRIT  Enhanced Suppression
of the Platelet IIb/IIIa Receptor with Integrilin Therapy; IMPACT-II  Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis; RESTORE  Randomized
Efficacy Study of Tirofiban for Outcomes and Restenosis.
Table 3. Comparison of Bleeding Risk in ESPRIT and IMPACT-II Patients Using TIMI
Major/Minor Bleeding Criteria
ESPRIT IMPACT-II
Treatment Arm Placebo Arm Treatment Arm Placebo Arm
Median ACT (Q1, Q3) 273 (234, 315) 263 (230, 300) 356 (324, 394) 344 (316, 380)
Major/minor bleeding 4.4% 2.4% 17.4% 14.4%
ACT (s)
200–249 4.20% 3.75% 31.25% 18.18%
250–299 5.02% 1.63% 16.13% 13.68%
300–349 2.86% 2.88% 15.11% 13.62%
350–399 1.28% 1.89% 18.08% 15.41%
400–449 6.45% 0 18.75% 16.67%
Data are presented as the median value (25th and 75th percentiles) and percentage of subjects.
TIMI  Thrombolysis in Myocardial Infarction; other abbreviations as in Table 2.
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was likewise low for the placebo group at lower ACT levels.
This was true for TIMI definitions of bleeding as major,
minor, or a combination of the two (Fig. 3).
Chew et al. (5) recently reported the results of a meta-
analysis of six randomized trials of patients undergoing PCI.
In this study, when the degree of heparin anticoagulation
was compared with ischemic and bleeding end points, the
risk of ischemic end points was progressively reduced with
increasing ACT levels, with no observed upper limit of
efficacy. The ACT also correlated with bleeding events,
with the lowest event rates seen in the range of 325 to 350 s.
Important differences between this meta-analysis and the
current study deserve emphasis. The patients analyzed by
Chew et al. (5) represented a heterogeneous population with
a broad range of indications for intervention, as well as
available technologies at the time of the individual studies.
The analysis included studies spanning almost a decade, a
time during which major pharmacologic and technologic
advances were made in interventional cardiology. Of the
more than 15,000 patients studied, only 1,221 (7.7%)
received a coronary stent. Generally, 8F or 10F sheaths were
used, and only a small minority of patients received ticlo-
pidine or clopidogrel. Compared with traditional anticoag-
ulation regimens (16–18), these agents have been associated
with significant reductions in bleeding events after coronary
stent implantation. The association between ACT and
Figure 5. Comparison of bleeding probabilities between IMPACT-II and ESPRIT patients receiving placebo. ACT  activated clotting time.
Figure 6. Comparison of bleeding probabilities between IMPACT-II and ESPRIT patients receiving treatment. ACT  activated clotting time.
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ischemic complications may be more relevant in balloon
angioplasty cases in which inflation times, as well as overall
procedure duration, are typically longer than with coronary
stenting. A similar relationship between heparin anticoag-
ulation and the risk of abrupt closure in angioplasty patients
(not undergoing routine stenting) was observed by Bittl et
al. (19).
Study limitations. Patients were not randomized in terms
of heparin dosing or ACT. Although an ACT of 200 to
250 s was associated with optimum safety and efficacy in this
study, we cannot state definitively that this is the best
possible level of anticoagulation. Whether an ACT of
200 s would have provided adequate anticoagulation could
not be addressed. Bleeding rates were extremely low in this
study, and we did not have adequate statistical power to
detect differences in bleeding for increases in ACT. Given
these low overall rates, however, it does not appear that
extreme values of ACT were associated with increased
bleeding. The sample size also did not provide adequate
statistical power to detect differences in rare thrombotic
complications, such as peripheral embolism or stroke and
vascular thrombosis. However, none of these adverse events
occurred in either group in the 2,064 patients in the study.
Clinical implications. This study extends our understand-
ing of the relationship between heparin anticoagulation and
important clinical outcomes in patients undergoing PCI.
There was no minimum ACT below which there was a
tradeoff between bleeding and ischemic events. Ischemic
events did not significantly increase in the lowest ranges of
ACT—a finding that remained constant for both the
eptifibatide and placebo-treated patients. Based on this
analysis, an ACT of 200 to 250 s appears to be reasonable
in terms of safety and efficacy in a contemporary treatment
setting. Further reductions in heparin dosing during PCI
should be investigated in a prospective, controlled study.
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